Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents.
about
Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapyProtein Nanospheres: Synergistic Nanoplatform-Based Probes for Multimodality Imaging.Polymeric micelles in anticancer therapy: targeting, imaging and triggered release.In vivo imaging of molecular targets and their function in endocrinology.Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model.Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancerDevelopment and application of a multimodal contrast agent for SPECT/CT hybrid imaging.Radioactive holmium acetylacetonate microspheres for interstitial microbrachytherapy: an in vitro and in vivo stability study.Cellular magnetic resonance imaging: in vivo imaging of melanoma cells in lymph nodes of miceMRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation.A multifunctional contrast dye for morphological research.Holmium nanoparticles: preparation and in vitro characterization of a new device for radioablation of solid malignancies.Quantitative Monte Carlo-based holmium-166 SPECT reconstruction.Intratumoral injection of radioactive holmium ( (166) Ho) microspheres for treatment of oral squamous cell carcinoma in cats.Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).The physics of radioembolization
P2860
Q28066010-D7DB8EA7-D186-4B85-BBAE-16DBF8ED2196Q30465976-67A69A9E-B23D-49E4-907B-004ADF43246CQ30478123-647D771E-B2B1-4D81-B95D-C54C29FD3546Q33637199-E7C61703-4128-4010-A1C2-68642E5DF8BDQ33715683-F2A55BF0-8977-4BAA-8CE0-2891BFB03772Q34548164-A02EACC8-E523-49B9-B7C4-3B69FC988B5AQ35479563-F1016F85-3130-41DB-A555-8794B4921E87Q35761648-8D2EFC4B-51F3-4A0C-8391-24E75A25D683Q36485270-2BFB3B66-2B12-4F6B-8A63-F948423ECC8BQ36586434-77786A54-D30A-4E71-9580-087DE23D47F7Q40343160-F489BCC6-CB82-464B-A7D6-8C49FCE04E75Q41869357-0860A0C5-52C3-4CD6-9E63-99A3EB01B48EQ45369216-102BE9A6-F828-4501-9F15-580EA885B680Q48180081-5F8935D8-8C18-4643-B0C6-6CFADC603452Q55434794-7A1B2BC9-CD18-4384-9234-6FD8B41CC1A7Q58616102-C850A2E4-3636-428E-9661-861146F297FC
P2860
Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Factors affecting the sensitiv ...... nostic and therapeutic agents.
@en
type
label
Factors affecting the sensitiv ...... nostic and therapeutic agents.
@en
prefLabel
Factors affecting the sensitiv ...... nostic and therapeutic agents.
@en
P2093
P1476
Factors affecting the sensitiv ...... nostic and therapeutic agents.
@en
P2093
Alfred D van Het Schip
Chris J G Bakker
Freek J Beekman
Jan-Henry Seppenwoolde
Johannes F W Nijsen
Peter R Seevinck
Tim C de Wit
P304
P356
10.2174/187152007780618153
P577
2007-05-01T00:00:00Z